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ABSTRACT
Due to the essential role macrophages play in antiviral immunity, it is important to understand the intracellular andmolecular
processes that occur in macrophages following infection with various strains of vaccinia virus, particularly those used as vaccine
vectors. Similarities as well as differences were found in macrophages infected with different poxvirus strains, particularly at the
level of virus-induced apoptosis and the expression of immunomodulatory genes, as determined bymicroarray analyses. Inter-
estingly, the attenuated modified vaccinia Ankara virus (MVA) was particularly efficient in triggering apoptosis and beta inter-
feron (IFN-) secretion and in inducing changes in the expression of genes associated with increased activation of innate immu-
nity, setting it apart from the other five vaccinia virus strains tested. Taken together, these results increase our understanding of
how these viruses interact with humanmacrophages, at the cellular andmolecular levels, and suggest mechanisms that may un-
derlie their utility as recombinant vaccine vectors.
IMPORTANCE
Our studies clearly demonstrate that there are substantial biological differences in the patterns of cellular gene expression be-
tweenmacrophages infected with different poxvirus strains and that these changes are due specifically to infection with the dis-
tinct viruses. For example, a clear induction in IFN-mRNAwas observed after infection withMVA but not with other poxvi-
ruses. Importantly, antiviral bioassays confirmed that MVA-infected macrophages secreted a high level of biologically active
type I IFN. Similarly, the phagocytic capacity of macrophages was also specifically increased after infection withMVA. Although
the main scope of this study was not to test the vaccine potential of MVA as there are several groups in the field working exten-
sively on this aspect, the characteristics/phenotypes we observed at the in vitro level clearly highlight the inherent advantages
that MVA possesses in comparison to other poxvirus strains.
Efficient antiviral immunity involves both innate and adaptiveimmune responses. Macrophages and dendritic cells (DCs)
are specialized antigen-presenting cells (APCs) that play an im-
portant role in the innate defense against infection, clearance of
infected host cells and molecules, and presentation of viral anti-
gens. Being widely dispersed throughout the body, DCs and mac-
rophages participate in the initial capture and processing of for-
eign antigens (innate immunity), leading to the subsequent
activation of specific T and B cell effector mechanisms (adaptive
immunity). In addition to their efficient phagocytic and antigen
presentation activities, these phagocytes are also strong regulators
of local and systemic immune responses through the secretion of
chemokines and cytokines (1). For example, macrophages are
equipped with a broad range of pathogen recognition receptors
that make them efficient at recognizing foreign viral antigens and
producing inflammatory cytokines (2).
The Poxviridae are a family of linear double-stranded DNA
viruses that replicate entirely in the cytoplasm of infected cells.
While smallpox has been eradicated, interest in poxvirus-derived
vectors remains high due to their inherent immunogenic proper-
ties, including the ability to induce long-term humoral and cell-
mediated immunity (2).Modified vacciniaAnkara virus (MVA), a
highly attenuated strain of the poxvirus vaccinia virus (VACV)
generated after more than 500 passages in chicken embryo fibro-
blasts, is considered to be a potent vaccine vector candidate due to
its high immunogenic properties (3–5). MVA replicates well in
vitro in avian cells but is largely replication deficient in human and
othermammalian cells, includingHeLa andBSC40 cells (3). Thus,
MVA-based recombinants have been effectively used inmammals
to induce protective immunity against a wide spectrum of patho-
gens (6, 7), and their immunogenic potential is currently being
tested in phase I/II clinical trials against HIV-1, malaria, and nu-
merous solid tumors (8–11).MVA is also a potentially safe vaccine
candidate for smallpox should this virus reemerge as a bioterrorist
weapon (12). NYVAC is an attenuated derivative of the VACV
Copenhagen strain (CopV), from which 18 open reading frames
(ORFs) were specifically deleted from the parental viral genome,
including those involved in host range, virulence, and pathogen-
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esis (13). NYVAC-derived vectors are able to express antigens
from a broad range of species (13) and have been used as recom-
binant vaccines against numerous pathogens and tumors (1, 14–
16), and phase I/II clinical trials usingNYVAC againstHIV-1 have
shown strong and specific immunogenicity and a good safety pro-
file (17). Themost frequently studied nonattenuatedVACV strain is
Western Reserve (WR), a mouse brain-passaged derivative of the
New York Board of Health (NYBH) vaccinia virus (18), one of the
most widely used vaccinia viruses in the smallpox eradication pro-
gram and the basis of the only commercially approved smallpox vac-
cine (Dryvax) available for limited use in the United States (19).
Since macrophages are one of the key cell types for initiating
inflammatory and immune responses to numerous viruses (20,
21), we aimed to study, in these professional APCs, the virus cycle
of poxvirus-derived vectors due to their multiple applications in
immunology and vaccinology. Specifically, we characterized the
impact of infection of primary human macrophages with a panel
of six poxvirus vectors. Our studies show that there are substantial
biological differences in the patterns of cellular proteins and genes
expressed between macrophages infected with different poxvirus
strains, and the changes observed differed between nonattenuated
and attenuated vaccinia vectors. For example, a strong and clear
induction in beta interferon (IFN-) mRNA expression was ob-
served in macrophages after infection with the attenuated strain
MVA and to a lesser degree with NYVAC but not with other non-
attenuated poxviruses. Importantly, antiviral bioassays confirmed
that MVA-infected macrophages secreted high levels of biologi-
cally active type I IFN, and the phagocytic capacity of macro-
phages was also specifically increased after infection with MVA.
Thus, our results clearly highlight the inherent immuno-stimula-
tory advantages that attenuated vaccinia virus vectors, specifically
MVA, possess in comparison to other poxvirus strains.
MATERIALS AND METHODS
Cells, viruses, and infection conditions. BSC40 and BHK-21 cells have
been previously described (22). Human blood was obtained from healthy
donors, and peripheral blood mononuclear cells (PBMCs) were isolated
from buffy coats following standard protocols (2). (This study received
the approval of the Committee of Ethics and Clinical Investigation of the
Universidad Autónoma de Madrid [Spain].) Briefly, whole blood was
layered on top of a Ficoll cushion (Ficoll-Plaque Plus; GEHealthcare) and
centrifuged at 1,800 rpm for 30 min at room temperature. The lympho-
cyte/monocytic fraction was isolated, washed with 1 phosphate-buff-
ered saline (PBS) and subjected to red blood cell lysis (ammonium chlo-
ride solution; Stem cell Technologies) for 5min at room temperature, and
following an additional wash with 1 PBS, monocytes were cultured un-
der adherent conditions in 1 RPMI medium (Gibco) supplemented
with 10% fetal bovine serum (FBS) in a humidified atmosphere with 5%
CO2 at 37°C. Adhered monocytes were cultured for 7 to 10 days to allow
for differentiation into macrophages.
The poxvirus strains used in this work were kindly provided by
Mariano Esteban and Antonio Alcamí. NYVAC and MVA strains were
propagated in BHK-21 cells. WR, vaccinia virus Ankara (ANK), CopV,
andNYCBHwere grown in BSC40 cells. All of the strains were purified by
centrifugation through a sucrose cushion, followed by sucrose gradient
fractionation (23), and then titers were determined by plaque assay on
BSC40 cells for all strains except MVA, for which titers were determined
by immunostaining on BHK-21 cells with a polyclonal anti-VACV anti-
body as previously described (22).
Analysis of virus growth. To determine virus growth profiles, macro-
phages grown in 24-well tissue culture plates were infected in triplicate
with MVA, ANK, WR, NYBH, NYVAC, or CopV at a multiplicity of
infection (MOI) of 0.1 PFU/cell. Following virus adsorption for 60min at
37°C, the inoculum was removed, and infected cultures were incubated
with fresh Dulbecco’s modified Eagle’s medium (DMEM) containing 2%
fetal calf serum (FCS) at 37°C in a 5%CO2 atmosphere. At different times
postinfection (p.i.) (0, 24, and 48 h), cells were removed by scraping,
subjected to three freeze-thaw cycles, and briefly sonicated, and virus
yields were determined by plaque assay on BSC40 cells for each virus
exceptMVA, for which the titers were determined by immunostaining on
BHK-21 cells.
Metabolic labeling of proteins. Macrophages were mock infected or
infected with MVA, ANK, WR, NYBH, NYVAC, or CopV (5 PFU/cell),
and at the indicated times (see Fig. 3A), 1  106 cells were washed with
methionine-free medium and incubated in methionine-free medium
containing [35S]methionine (50 Ci/well) for 30 min at 37°C. Proteins
from cell extracts, prepared in lysis buffer, were fractionated by 12% SDS-
PAGE and developed by autoradiography.
Western blotting. A total of 1 106 macrophages were infected with
MVA, ANK,WR, NYBH, NYVAC, or CopV at anMOI of 5 PFU/cell, and
at 2, 6, and 16 h p.i., cells were collected and lysed in lysis buffer (50 mM
Tris-HCl, pH 8.0, 0.5 M NaCl, 10% NP-40, 1% SDS) for 5 min on ice.
Protein lysates (100 g) were fractionated by 14% or 8% SDS-PAGE,
transferred to nitrocellulose membranes, and incubated with anti-poly-
(ADP-ribose) polymerase (PARP; Cell Signaling, Boston,MA), anti-actin
(Santa Cruz, Santa Cruz, CA), anti-E3L (kindly provide by the Beltram
Jacobs lab), anti-B5R (Bei Resources), anti-A27L (Bei Resources), anti-phos-
pho-eIF-2 (eIF-2-P; Biosource, Camarillo, CA), or anti-eIF-2 (Santa
Cruz) antibody, followed by secondary antibodies (mouse and rabbit perox-
idase conjugates). Protein expression was detected using enhanced chemilu-
minescence (ECL) reagents (Amersham, Uppsala, Sweden).
Microarray labeling. Ultraspect-II RNA (Biotecx, Houston, TX) was
used to isolate total RNA from primary human macrophages infected
with MVA, ANK, WR, NYBH, NYVAC, or CopV (3 106 cells/time p.i.;
5 PFU/cell) or mock infected (mock). RNA was then purified with Mega-
clear (Ambion, Foster City, CA), and integrity was confirmed using an
Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). Total RNA (1.5 g)
was amplified with an Amino Allyl MessageAmp aRNA kit (Ambion); 54
to 88g of amplified RNA (aRNA)was obtained. Themean RNA size was
1,500 nucleotides, as observedusing anAgilent 2100Bioanalyzer. For each
sample, 6 g of aRNA was labeled with Cy3 or Cy5 mono-NHS (N-
hydroxysuccinimide) ester (CyDye Postlabeling Reactive Dye Pack; GE
Healthcare) and purified using Megaclear. Cy5 and Cy3 incorporation
was measured using 1 l of probe in a Nanodrop spectrophotometer
(Nanodrop Technologies). For each hybridization, Cy5 and Cy3 probes
(150 mol each) were mixed and dried by speed vacuum and resuspended
in 9l of RNase-free water. Labeled aRNAwas fragmented by adding 1l
of 10 fragmentation buffer (Ambion), followed by incubation at 70°C
for 15 min. The reaction was terminated with 1 l of stop solution (Am-
bion). Two dye-swapped hybridizations were performed for each com-
parison: in one, themock-infected samplewas Cy3 labeled, and theMVA-
infected sample was Cy5 labeled; in the second, labeling was reversed.
Double labeling was used to abolish dye-specific labeling and hybridiza-
tion differences.
Slide treatment and hybridization. Slides containing 22,264 spots
(19,256 different oligonucleotides) corresponding to theHumanGenome
Oligo set, version 2.2 (Qiagen, Hilden, Germany), were obtained from the
Genomic and Microarrays Laboratory (Cincinnati University, OH). In-
formation about printing and the oligonucleotide set can be found at http:
//microarray.uc.edu. Slides were prehybridized and hybridized as de-
scribed previously (24–27). Images from Cy3 and Cy5 channels were
equilibratedandcapturedwithanAxon4000Bscanner, and spotswerequan-
tified using GenePix, version 5.1, software. Data for replicates were analyzed
using Almazen software (Bioalma, Spain). In general, lowest normalization
was applied to each replicate, and the log ratios were merged with the corre-
sponding standard deviation and z-score.
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Gene expression analysis. The original data set contained 19,256 oli-
gonucleotides per slide. In each analysis, genes with an interreplicate
mean signal of 100 or an interreplicate standard deviation of 1 were
filtered out. Genes were considered to be differently expressed if the fold
change in expression was 2 (downregulated) or 2 (upregulated).
Functional analyses of regulated genes were generated by Ingenuity Path-
ways Analysis (Ingenuity Systems, Redwood City, CA). Hierarchical clus-
tering was carried out using the software SpotFire Decision Site for Func-
tional Genomics. Ward’s method with the average value ordering
function and half squared Euclidean distance function was used.
Latex bead phagocytosis.Humanmacrophages were seeded in eight-
well -Slide microscopy chambers (Ibidi, Germany) and filmed after in-
cubationwith 1-m-diameter latex beads conjugated to green fluorescent
protein (GFP) (Sigma) at a ratio of 10 beads per cell. Alternatively, cells
were cultured on coverslips and incubated for 1 h with the beads (20 or 10
beads per cell, depending on the experiment), washed three timeswith 1
PBS, and incubated with DMEM for an additional hour as described pre-
viously (28). Cells were fixed with 4% paraformaldehyde (PFA) and pro-
cessed for immunofluorescence analysis. Briefly, cells were washed with
phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde, and
permeabilized with 0.1%Triton X-100 in PBS at room temperature for 10
min, andDNAwas stainedwith ToPro 3 (Life Technologies). Imageswere
obtained using a Bio-Rad Radiance 2100 confocal laser microscope.
Determination of caspase 3/7 activation. Apoptosis quantification
was carried out using the Caspase-Glo 3/7 assay kit (Promega) according
to the manufacturer’s protocol. Briefly, human macrophage monolayers,
grown in 96-well plates, were infected at anMOI of 5 PFU/cell, and at the
indicated times p.i., 100 l of Caspase-Glo 3/7 reagent was added to the
wells. Plates were gently shaken and then incubated in the dark at 20°C for
60 min before luciferase activity was recorded using an Orion microplate
luminometer (Berthold Technologies).
Quantitative real-time RT-PCR. Total RNA was isolated from mac-
rophages uninfected or infected with MVA, ANK, WR, NYBH, NYVAC,
or CopV (5 PFU/cell) with Ultraspect-II RNA reagent (Biotecx), accord-
ing to the manufacturer’s instructions. One microgram of RNA was re-
verse transcribed using SuperScript (Invitrogen) with oligo(dT) as a
primer. A 1:40 dilution of the reverse transcription (RT) reactionmixture
was used for quantitative PCR (qRT-PCR). Primers and probe sets used to
amplify tumor necrosis factor alpha (TNF-; probe Hs00174128_m1),
IFN-stimulated gene 15 (ISG15; Hs00192713_m1), interleukin-7 (IL-7;
Hs00978525_m1), IFN- (Hs01652729_s1), andNF-	2 (Hs0128892_g1)
were purchased from Applied Biosystems. RT-PCRs were performed ac-
cording to Assay-on-Demand, optimized for TaqMan Universal PCR
MasterMix, no AmpErase UNG, as described previously (26). All samples
were assayed in triplicate. Threshold cycle (CT) values were used to plot a
standard curve in which theCT value decreased in linear proportion to the
log of the template copy number. The correlation values of standard
curves were always99%.
VSV antiviral assay.Vero cells left either untreated or pretreated with
either IFN- (1,000 U ml1 for 16 h) or with the supernatant obtained
from MVA-infected macrophages from three independent donors were
infected with vesicular stomatitis virus (VSV; 0.1 PFU/cell). VSV titers
were quantified by plaque assay onVero cells as previously described (29).
RESULTS
Attenuated and nonattenuated poxvirus vectors induce CPE in
primary humanmacrophages independent of viral replication.
Due to the facts that (i) macrophages are one of the first immune
cells to encounter viral pathogens and (ii) these professional APCs
are critically important in activating the immune system, it is im-
portant to study the biology of viral infections in these cells in
order to understand how macrophages might participate in me-
diating an effective immune response against viruses such as pox-
viruses. To this end, we characterized the phenotypic, intracellu-
lar, and molecular changes in macrophages following infection
with the attenuated vaccine vectors MVA and NYVAC and the
nonattenuated wild-type strains ANK and CopV as well as WR
and its derivative strain NYBH. We first defined the induced cy-
topathic effect (CPE) in macrophages at 2, 6, and 16 h postinfec-
tion (p.i.) with all six virus strains. Peripheral bloodmononuclear
cells (PBMCs) were isolated from buffy coats, and macrophages
were enriched by growth under adherent conditions. The purity of
monocyte cultures was confirmed by CD14 labeling and flow cy-
tometry analysis (average, 89% of CD14-positive cells) (data not
shown). Primarymacrophages were infectedwith all six VACVs at
an MOI of 5 PFU/cell. As early as 2 h p.i., we observed in all cases
various degrees of CPE, characterized by changes in cell morphol-
ogy, including cell rounding and cytoplasmic contraction (Fig.
1A), with more severe effects noted at 16 h p.i. To evaluate
whether the differences in CPE were due to variations in viral
production, we determined the intracellular titers of infectious
virus at 48 and 72 h following infection of human macrophages
with all six VACV strains at an MOI of 0.1 PFU/cell. Titers were
determined using a standard plaque-forming assay for all VACVs
tested except MVA, for which the titers were determined by im-
munohistochemical staining as previously described (24) (Fig.
1B). Quantification of our titer results clearly demonstrated that
poxvirus infection in human macrophages is abortive as none of
the viral strainswas able to produce de novo infectious virions (Fig.
1C). To analyze which step in the viral cycle was blocked, we
examined viral protein synthesis in infected macrophages by
Western blotting using antibodies specific for early p25 (E3L) and
late p42 (B5R) and p14 (A27L) viral proteins (Fig. 2). The early
p25 (E3L) protein was detected in lysates from macrophages in-
fected with all of the viruses, indicating that all VACV strains
could synthesize early viral proteins regardless of their attenuation
state. In contrast, the late protein encoded by the B5R gene was
detectable only in lysates frommacrophage infected with the non-
attenuated strains ANK,WR, CopV, and NYBH, and the late pro-
tein p14 (A27L) was not detected in any of the lysates examined
(Fig. 2). Importantly, these results were validated by immunoflu-
orescence analysis (data not shown) and differ from previous re-
sults obtained in DCs infected with MVA, in which the late pro-
teins encoded by the A17L and A27L genes were detected in
infected DC lysates (30).
Attenuated and nonattenuated poxvirus vectors differen-
tially induce protein translation shutoff and apoptosis in pri-
mary humanmacrophages.We next examined the effect of pox-
virus infection on protein translation. In line with previous
observations (24), we observed total protein translational shutoff
following infection of macrophages with VACV. Specifically,
macrophages were metabolically labeled with [35S]methionine-
cysteine at 2, 6, and 16 h p.i. with all six VACV strains, and protein
lysates were analyzed by SDS-PAGE and autoradiography. We
observed a severe translational block in protein synthesis by 16 h
p.i. in cells infected with all viruses (Fig. 3A); however, the effect
was earlier (
6 h p.i.) and more pronounced following infection
with MVA and NYVAC. While this blockade in protein transla-
tion coincided with phosphorylation of eIF-2 (Fig. 3B) under all
conditions tested, the levels of phospho-eIF-2 were increased in
macrophages following infection withMVA or NYVAC (Fig. 3B).
Apoptosis is a very important innate immune response against
viral infections and is generally considered a self-defense mecha-
nism (17) as loss of infected cells should impair virus propagation
and further spread. Moreover, phagocytosis of apoptotic bodies
Poxvirus Interactions with Macrophages
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by APCs is an important mechanism for cross-presentation as
foreign antigens gain access to major histocompatibility complex
class I (MHC-I) molecules for priming of cytolytic T cells (31).
Viruses, however, resist this host defensemechanismby inhibiting
apoptosis via antiapoptotic viral proteins (32). Previously, we
reported that the attenuated poxviruses MVA and NYVAC in-
duce apoptosis in HeLa (27) and DCs (30); thus, DCs infected
with these viruses could putatively initiate an immune response
through cross-priming (i.e., with T cells) (33). To analyze whether
apoptosis also occurs in poxvirus-infected macrophages, we used
an antibody that recognizes both full-length and cleaved poly-
(ADP-ribose) polymerase-1 (PARP-1) to assess apoptosis in hu-
manmacrophages following infectionwith all six poxvirus strains.
In MVA-, NYVAC-, CopV-, and WR-infected macrophages, the
89-kDa cleaved PARP-1 protein was evident at 16 h p.i. (Fig. 3B),
indicating that these four poxviruses are capable of inducing
apoptosis in macrophages. In order to better appreciate and mea-
sure the level of apoptosis activation in these cells, a Caspase-Glo
3/7 assay kit was used as per the manufacturer’s instructions. As
shown in Fig. 3C, MVA, CopV, and NYVAC markedly induced
apoptosis in comparison to ANK, WR, and NYBH, where little to
no caspase 3/7 activation was detected. Along these lines, we also
examined rRNA integrity in poxvirus-infectedmacrophages and ob-
served pronounced RNA degradation in macrophages infected with
MVAandNYVACat 16hp.i. (Fig. 3D).Together, these results reveal
thatof thepoxvirus vectors tested,MVAis themostpotent inducerof
apoptosis, while NYVAC and CopV can also induce apoptosis to
different degrees and likely via different mechanisms.
Differential gene regulation in macrophages infected with
attenuated and nonattenuated poxvirus vectors. To study the
cellular and molecular changes mediated by each poxvirus vector
in more detail, microarray analyses were performed. Since the
majority of the cellular changes we observed (Fig. 1 and 2) oc-
curred by 6 h p.i. and before the onset of rRNA degradation (Fig.
3D), cDNA from 6-h mock-infected or 6-h poxvirus-infected
macrophages was hybridized to SurePrint G3 Human Gene Ex-
FIG 1 Cellular changes in primary humanmacrophages following infection with different poxvirus vectors. (A)Morphological changes in humanmacrophages
mock infected or infectedwithMVA, ANK,WR,NYBH,NYVAC, or CopV (5 PFU/cell) in six-well plates. Changes were examined by phase-contrastmicroscopy
at 2, 6, and 16 h p.i. (hpi). For each group of infections, representative fields are shown at a magnification of40. (B) Titration of each viral strain. MVA titers
were determined by immunostaining using BHK-21 cells; ANK, WR, NYBH, NYVAC, and CopV titers were determined by plaque assay on BSC40 cells. The
images show differential plaque sizes produced by the different poxvirus-derived vectors. (C) VACV growth in infected humanmacrophages. Cells were infected
withMVA,ANK,WR,NYBH,NYVAC, or CopV (0.1 PFU/cell), and at the times indicated, cells were harvested, and virus yields were determined by plaque assay
for each virus except MVA, for which the titer was determined by immunostaining. Results represent the means the standard deviations of three independent
experiments. P values from a two-tailed t test assuming nonequal variance were determined. In all the cases, P is0.01. T, time.
Royo et al.
5514 jvi.asm.org Journal of Virology
 o
n
 O
ctober 23, 2014 by UAM
/SERVICIO
 DE DO
CUM
ENTACIO
N
http://jvi.asm.org/
D
ow
nloaded from
 
pression Microarrays (Agilent), and results were analyzed as de-
scribed previously (34). Using this approach, we identified genes
up- and downregulated in macrophages infected with each pox-
virus vector (see Table S1 in the supplemental material) and sub-
sequently determined pathways that were similarly modulated by
the majority of the poxvirus strains tested and some that were
distinctly altered using the Ingenuity Pathways Analysis software
(Ingenuity Systems, Redwood City, CA).
Of the six poxvirus vectors tested, MVAmodulated the largest
number of genes, while ANKmodulated the least number of genes
(Fig. 4A). When the four nonattenuated vectors were compared,
we observed that whileWR, NYBH, and CopVmodulated similar
genes, the genes modulated by ANK infection were distinct and
different. Furthermore, when we compared the nonattenuated
poxvirus vectors ANK and CopV to their respective attenuated
derivatives MVA and NYVAC, respectively, we observed that of
the 6,110 genes upregulated and 6,690 genes downregulated by
MVA, only 596 (
9%) and 794 (
12%) genes were also modu-
lated by ANK, respectively, while NYVAC and CopV and even
MVA and NYVAC modulated many of the same genes (35%)
(Fig. 4B). Thus, excluding ANK, the infection-induced gene ex-
pression changes in WR-, NYBH-, CopV-, MVA-, and NYVAC-
infected cells were largely similar. In the case of WR infection, the
gene-specific changes observed in this study are quite different
from those previously observed in HeLa cells (26).
As the goal of our study was to identify poxvirus vectors that
modulate immune signaling pathways in a way that would sup-
port activation of an antiviral immune response, we next assessed
the pathways modulated by each poxvirus, focusing on genes and
pathways involved in IFN, Toll-like receptor (TLR), and interleu-
kin signaling, as well as apoptosis and NF-	B and phosphatidyl-
inositol 3-kinase (PI3K)/AKT signaling. Compared to the nonat-
tenuated poxvirus strains, probably due to the absence of certain
viral genes, infection with MVA and NYVAC was associated with
the modulation of a larger number of pathways and genes in-
volved in immune signaling and activation (Fig. 4C), such as IFN
and interleukin signaling as well as NF-	B- and PI3K/AKT-medi-
ated pathways (Table 1; see also Fig. S1 in the supplemental ma-
terial). At the gene level, beta 1 interferon (IFN1), tumor and
proinflammatory cytokines such as TNF- and IL-29, chemokine
receptors CXCR5 and CXCR6, and antiviral response genes such
as CD70 and interferon-induced transmembrane protein 1
(IFITM1) were uniquely upregulated or significantly higher in
MVA- and NYVAC-infected macrophages. Interestingly, while
IL-29 was upregulated, other interleukins such as IL-1, IL-7, and
IL-6 were strongly downregulated in all samples (Fig. 5A; see also
Fig. S1), which interestingly differs from our previous studies in
DCs where IL-6 was upregulated (30).
Importantly we validated many of the genes shown in Table 1
by real-time RT-PCR (Fig. 5A). In addition, to discard the possi-
bility that cellular debris present in the virus stock could account
for the observed changes in gene expression in macrophages fol-
lowing infection, mock inoculum was purified from uninfected
cells using the same protocol as for the purification of vaccinia
viruses. Mock inocula prepared from cultures of BHK-21 cells
were used as controls for MVA and NYVAC infections, andmock
inocula from BSC40 cells were used as controls for the other in-
fections. Infections of human macrophages with all the virus
strains and their respective mock controls were then carried out,
and the expression levels of a select group of genes (IFN-,
TNF-, and ISG15) were analyzed by real-time RT-PCR. Com-
pared to mock-infected cells, gene expression patterns similar to
our previous results (Fig. 5A) were observed (Fig. 5B), indicating
that the changes in the expression levels of genes postinfection are
due to intrinsic differences among the virus strains and not to the
presence of contaminants in the viral preparations.
Biological effectsof IFNpathwayactivation inMVA-infected
macrophages. Our microarray experiments indicated that infec-
tion of macrophages with the attenuated VACV strain MVA re-
sulted in a significant increase in the expression of a number of
cytokines (Table 1). For example, MVA elicited high induction of
IFN-, an important protein involved in the innate antiviral im-
mune response. To validate this result in vitro, we functionally
measured the presence of IFN- in the supernatant of MVA-in-
fected macrophages using a vesicular stomatitis virus (VSV)-
based antiviral assay. Specifically, VSV-infected Vero cells were
incubated with the supernatants of MVA-infected macrophages
from three donors, and at 48 h posttreatment, VSV titers were
determined. A clear inhibition of VSV infection in vitro was ob-
served after incubation withmedium fromMVA-infectedmacro-
FIG 2 Viral protein expression duringMVA, ANK,WR, NYBH, NYVAC, or CopV infection. Primary humanmacrophages weremock infected or infected with
the indicated poxviruses (5 PFU/cell), and at the indicated times p.i., equal amounts of proteins from cell extracts were fractionated by SDS-PAGE, transferred
to nitrocellulose membranes, and treated with antibodies to specific virus early (p25) and late proteins (p64 and p14). Molecular weight (MW; in thousands) is
indicated based on protein standards. In all blots, detection of actin was used as a loading control.
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phages (Fig. 6). These results clearly demonstrate that the in-
creased mRNA expression of type I IFN observed in MVA-
infected macrophages corresponds to increased translation and
release of this antiviral protein.
A major function of macrophages is the phagocytosis of patho-
gens, antigens, and infected or apoptotic cells, which is critical for
innate as well as for adaptive immunity. Recently, we reported that
the phagocytic capacity of macrophages is highly regulated by IFN
(35).Latexbeadsare a commonsubstrateused inbiochemical studies
to study phagocytosis in macrophages (28). Thus, to determine
whether the IFN produced in MVA-infected macrophages is critical
for thephagocytic capacity ofmacrophages,we analyzed the intakeof
GFP-labeled latex beads by confocal and time-lapse microscopy in
naive macrophages mock treated or treated with supernatants from
FIG 3 Protein synthesis inhibition, apoptosis induction, and rRNA breakdown during poxvirus infection of primary human macrophages. (A) Metabolic
labeling of proteins during MVA, ANK, WR, NYBH, NYVAC, or CopV infection. Human macrophages were mock infected or infected with the indicated
poxviruses (5 PFU/cell); at the times indicated, cells were labeled (30 min) with [35S]Met-Cys Promix (50 Ci/ml), and equal amounts of proteins were
subsequently analyzed by SDS-PAGE (10%) and autoradiography. Molecular weight (MW; in thousands) is indicated based on protein standards. (B) Time
course of PARP-1 cleavage duringMVA, ANK,WR, NYBH, NYVAC, or CopV infection. Humanmacrophages weremock infected or infected (5 PFU/cell) with
the indicated poxviruses, and at the times indicated, total protein (100 g) was fractionated by SDS-PAGE, transferred to nitrocellulose membranes, and
immunoblottedwith anti-PARP-1. An 89-kDa PARP-1 cleavage product was observed at 16 h p.i.Molecular weight standards (MW; in thousands) are indicated.
eIF-2 or phosphorylated eIF-2 (eIF-2-P) at Ser51 was measured using specific antibodies. (C) Quantification of cells undergoing apoptosis after infection
with MVA, ANK, WR, NYBH, NYVAC, or CopV. At 24 h hours after mock infection or infection with the indicated viruses (5 PFU/cell), cells were fixed, and
apoptosis was measured using a Caspase-Glo 3/7 assay kit. Results represent the means the standard deviations of three independent experiments. P values
from a two-tailed t test assuming nonequal variance were determined. In all the cases, P is0.05. DL, detection limit. (D)MVA or NYVAC infection of primary
human macrophages causes rRNA breakdown. Total rRNA was isolated from uninfected (mock) or poxvirus-infected macrophages (5 PFU/cell). At indicated
times p.i., 2 g of total RNA was separated by electrophoresis and subsequently stained with ethidium bromide. RNAs were also analyzed using an Agilent 2100
Bioanalyzer. RNA integrity numbers are listed under each corresponding sample.
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FIG 4 Number of host genes and pathway analysis of genes differentially regulated by poxvirus infection. (A) Shown are the numbers of cellular genes that
exhibited expression changes in our microarray analyses larger than 2-fold or less than 2-fold at 6 h after infection with each virus. (B) Intersections of gene
upregulation (fold change [fc] of2) or downregulation (fold change of2) inmacrophages infectedwith the indicated viruses are shown in theVenndiagrams.
(C) Ingenuity Pathway analysis showing selected canonical pathways significantly modulated in macrophages infected with the indicated poxviruses compared
to naive macrophage controls (P  0.05). The dashed line indicates the threshold set at 1.5 log (P value). ERK, extracellular signal-regulated kinase; MAPK,
mitogen-activated protein kinase; GM-CSF, granulocyte-macrophage colony-stimulating factor.
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MVA-infectedmacrophages from three donors. Time-lapsemicros-
copy analyses showed a marked increase in the phagocytosis of latex
beads inmacrophages treatedwith supernatants fromMVA-infected
macrophages compared to levels in untreated controls (Fig. 7 A).
Quantification of these results revealed that the phagocytic capacity
of treatedmacrophageswas
100 times higher than that observed in
untreated cultures (Fig. 7B). Taken together, these results strongly
suggest that the IFN produced from MVA-infected macrophages
may have an important immunogenic role, such as decreasing viral
replication and increasing the phagocytic capacity of APCs, two vital
processes necessary for the development of an effective antiviral im-
mune response.
DISCUSSION
Prior to the development of an effective adaptive immune re-
sponse, the innate immune systemprovides the first line of immu-
nological defense against a wide range ofmicroorganisms, includ-
ing bacteria and viruses (36). Macrophages and dendritic cells
(DCs) are specialized phagocytes that play an important role in
innate immunity and in the clearance of virus-infected cells. These
professional APCs are widely dispersed throughout the body and
are located in main portals of entry of microbes, such as the skin
and mucosal epithelia. They participate in the initial capture and
processing of potential antigens (innate immunity) and then in
the activation of specific T and B lymphocyte effectormechanisms
(adaptive immunity), resulting in immunological memory. A
comprehensive understanding of how immunity is generated, the
role of APCs in this process, and how the efficiency of this process
could be enhanced is essential for vaccine development.
Poxvirus vectors are efficient activators of host immune re-
sponses to virally expressed antigens of distinct origin and there-
fore are being used as potential vaccines for several pathogens and
TABLE 1 Representative genes regulated by poxviruses in infected macrophages involved in immune responsea
Pathway and gene
symbol Descriptionb
Fold change in expressionc
MVA NYVAC WR NYBH CopV ANK
Apoptosis inhibitors
BCL2 B-cell CLL/lymphoma 2 9.000 8.786 4.828 4.931 7.981 NS
BCL2A1 BCL2-related protein A1 4.175 2.544 4.471 3.388 4.715 NS
BCL2L1 BCL2-like 1 3.799 3.966 2.121 3.740 2.608 NS
MCL1 Myeloid cell leukemia sequence 1 (BCL2-related) 2.782 2.041 NS NS NS NS
NAIP NLR family, apoptosis-inhibitory protein 2.113 2.092 NS 2.308 4.057 NS
Apoptosis activators
FASLG Fas ligand (TNF superfamily, member 6) 39.393 10.768 NS 2.364 6.786 3.856
BAK1 BCL2-antagonist/killer 1 2.866 2.866 NS NS NS NS
CASP3 Caspase 3, apoptosis-related cysteine peptidase 2.285 NS NS 2.341 NS NS
CASP8 Caspase 8, apoptosis-related cysteine peptidase 2.331 2.141 NS NS NS NS
CASP10 Caspase 10, apoptosis-related cysteine peptidase 2.887 NS NS NS NS NS
DIABLO Diablo, IAP-binding mitochondrial protein 2.691 NS 3.967 2.251 3.654 NS
IFN signaling
IFNB1 Interferon beta 1, fibroblast 403.148 2.369 NS NS NS NS
IFNG Interferon gamma 23.457 5.430 3.656 7.697 10.565 NS
MX1 Myxovirus (influenza virus) resistance 1 3.426 13.306 7.458 8.109 6.898 NS
OAS1 2=-5=-Oligoadenylate synthetase 1, 40/46 kDa 3.932 6.136 11.467 3.997 7.923 NS
PIAS1 Protein inhibitor of activated STAT, 1 3.446 2.159 2.748 2.828 4.030 NS
TLR signaling
MYD88 Myeloid differentiation primary response 88 4.343 10.603 3.042 4.086 2.476 NS
TLR4 Toll-like receptor 4 6.389 4.153 5.010 2.736 3.323 NS
TLR7 Toll-like receptor 7 11.177 5.374 12.849 4.313 25.369 NS
NF-	B signaling
MAPK8 Mitogen-activated protein kinase 8 2.073 2.314 NS NS NS NS
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B cells
inhibitor, alpha
4.035 2.579 NS NS NS NS
TNF Tumor necrosis factor 2.560 4.075 7.124 7.025 12.289 NS
TAB3 MAP3K7 binding protein 3 5.469 6.867 7.504 2.340 6.524 NS
PI3K-AKT signaling
EIF4 Eukaryotic translation initiation factor 4E 2.350 2.114 NS NS NS NS
IKBKB Inhibitor of kappa light polypeptide gene enhancer in B cells,
kinase beta
2.061 NS 4.732 NS 3.521 NS
ITG3A Integrin, alpha 3 5.736 4.779 5.489 2.574 2.741 2.224
PDPK1 3-Phosphoinositide dependent protein kinase 1 3.446 2.185 NS NS NS NS
a Comparison of gene expression profiling for representative human genes specifically regulated by each vector according to predicted biological function.
b CLL, chronic lymphocytic leukemia; NLR, NOD-like receptor; IAP, inhibitor of apoptosis.
c NS, no significant modulation in gene expression.
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FIG 5 Validation of microarray data at the mRNA level. (A) RT-PCR analysis of the relative expression levels of immune response genes. Macrophages from three
donors weremock,MVA, NYVAC,WR, CopV, ANK, or NYBH infected and at 6 h p.i. were processed for RT-PCR analysis. The name of each gene product obtained
byRT-PCRanalysis is indicated. Three independent experimentswere carriedout, and a representative experiment is shown. Error bars indicate the standarddeviations
of the means. (B). Macrophages from three donors were MVA, NYVAC, WR, CopV, ANK, or NYBH infected. Mock inoculum is the uninfected cellular inoculum
purified using the same protocol for the purification of vaccinia virus. The purifiedmock inoculum from cultures of BHK-21 cells was used for comparisonswithMVA
andNYVACinfections, and thepurifiedmock inoculumfromBSC40cellswasused for comparisonswith theother infections (WR,CopV,ANK,andNYBH).Thename
of each gene product, microarray data values at 6 h p.i., and values obtained by RT-PCR analysis are indicated. Three independent experiments were carried out, and a
representative experiment is shown. Error bars indicate the standard deviations of the means.
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tumors (6, 17, 37). In the present study, we have characterized the
infection of macrophages with different poxvirus vectors to gain a
better understanding of how these vectors activate specific im-
mune responses in these APCs. We determined that poxvirus in-
fection in human macrophages is abortive as none of the viral
strains was able to produce de novo infectious virus; however, we
observed that macrophages infected with all the poxvirus strains
underwent extensive morphological damage at late times postin-
fection, which, at the intracellular level, was characterized by se-
vere inhibition of protein synthesis by 6 h p.i. and the induction of
apoptosis and rRNA degradation at 16 h p.i. In spite of a general
translational block induced by these viruses, some of the early
(p25) and late (p42, p14) viral proteins examined were produced
in infected cultures although differences were observed between
the attenuated and nonattenuated vectors (Fig. 2). For example, in
contrast to the nonattenuated poxvirus strains analyzed, MVA-
and NYVAC-infected macrophages did not produce the late viral
protein p42 encoded by the viral gene B5R. This clear difference
might be related to the degree and extent of eIF-2 phosphoryla-
tion and RNA degradation induced during infection with these
two attenuated strains as well as the presence or absence of certain
viral genes in the poxvirus virions. Perhaps forMVA andNYVAC,
the absence of B5R translation (Fig. 2) may be due to early eIF-2
phosphorylation and subsequent inactivation of the cellular trans-
lational machinery, while in macrophages infected with the non-
attenuated poxviruses, the delayed phosphorylation of eIF-2
may have allowed for the translation of the protein encoded by the
B5R gene. Deciphering the putative viral genetic elements that are
responsible for these differences may prove potentially useful for
developing vaccinia vectors that require early protein transla-
tional shutoff.
We next performed genomic studies to dissect the impact of
infection of human macrophages with each poxvirus strain. Hav-
ing observed profound morphological and intracellular effects
(e.g., apoptosis and rRNAdegradation) in humanmacrophages at
a late time postinfection (i.e., 16 h p.i.), we performed gene ex-
pression profiling analyses in primary humanmacrophages at 6 h
postinoculation with each vaccinia virus vector. Our gene profil-
ing analyses clearly demonstrated substantial biological differ-
ences in the expression patterns of cellular genes between macro-
phages infected with different poxvirus strains, and the observed
changes were specifically due to infection with each distinct viral
vector (Fig. 4 and Table 1; see also Table S1 and Fig. S1 in the
supplemental material).
While genes involved in hundreds of pathways were similarly
and differentially modulated by each poxvirus, we were specifi-
cally interested in determining if genes involved in innate immune
responses were differentially regulated based on the vaccinia virus
vector utilized. For example, proinflammatory cytokines such
TNF- and type I IFN and TLR signaling represent first-line de-
fenses against viral infections by generating an intracellular envi-
ronment that restricts viral replication (38–40). Type I IFN signal-
ing is considered the most effective antiviral immune response
mechanism of the innate immune system. IFN gene expression is
regulated by interferon regulatory factor 3 (IRF-3) phosphoryla-
tion, homodimerization, and nuclear translocation (41), leading
to the transcriptional activation of IRF-responsive genes, such as
IL-29 and IFN1. Our microarray experiments showed clear up-
regulation of IFN1 levels afterMVA andNYVAC infection (403-
and 2.4-fold, respectively) comparedwithWR,NYBH,CopV, and
FIG 6 Antiviral bioassays confirm that MVA-infected macrophages secreted
high levels of biologically active type I IFN. Plaque assay analysis of VSV-
infected Vero cells left either untreated or pretreated with either IFN- (1,000
U ml1 for 16 h) or with the supernatant (S) obtained from MVA-infected
macrophages from three independent donors. Results represent the means
the standard deviations of three independent experiments.
FIG7 MVA infection increases the phagocytosis of GFP-labeled latex beads in
human macrophages. (A) Phagocytosis of GFP-latex beads by human macro-
phages. Cells were seeded in eight-well tissue culture plates and treated with
supernatant (sup) frommock-infected (Uninfected) orMVA-infectedmacro-
phages for 16 h. After that, the cells were incubated with 1-m-diameter latex
beads conjugated to GFP in a ratio of 10 latex beads per cell. Phagocytized
beads and cells were visualized 2 h after latex bead incubation by phase-con-
trast microscopy. Representative fields are shown at a magnification of 40.
(B) Cells having phagocytized GFP-labeled latex beads were quantified by
immunofluorescence microscopy. Representative phase-contrast images are
shown. The graph shows the quantification of phagocytic cells in macrophage
cultures treated with supernatant (sup) from mock-infected (Uninfected) or
MVA-infected macrophages. Results represent the means the standard de-
viations of three independent experiments. P values from a two-tailed t test
assuming nonequal variance were determined. In all cases, P is0.05.
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ANK infection, where no change in IFN1 gene expression was
detected (Table 1). Likewise, we also observed a significant up-
regulation of IL-29 (
43-fold) but only in MVA-infected macro-
phages. This apparent and specific activation of type I IFN by
MVA was validated at the gene level by quantitative RT-PCR
(qRT-PCR) analyses and at the protein level using an antiviral
assay to assess IFN-mediated inhibition of VSV, as previously de-
scribed (42) (Fig. 5A and B and 6A). We also assessed the expres-
sion of other IFN-related genes, such ISG15, which we have pre-
viously shown to be an important antiviral player in VAVC
infections andmacrophage phagocytosis (35).Wehave previously
reported that type I IFN treatment increases latex bead uptake in
macrophages (35); therefore, to determine if the IFN signaling
stimulation produced after MVA infection could also potentiate
the phagocytic potential of naive macrophages, we treated pri-
mary cultures of macrophages with supernatant from uninfected
or MVA-infected macrophages and performed a phagocytosis as-
say using GFP-labeled latex beads. Time-lapsemicroscopy images
indicated that naive macrophages incubated with supernatants
from MVA-infected macrophages increased their phagocytic ca-
pacity compared tomacrophages incubated with control medium
alone (data not shown). Quantification of these results revealed
that after incubation with MVA-infected macrophage-condi-
tioned supernatant, 80%of themacrophages showed clear phago-
cytosis, while the amount of phagocytosis observed in cells treated
with supernatant from mock-infected cells was 
58% (Fig. 7B).
These results indicate that soluble factors released after MVA in-
fection enhance the phagocytic activity ofmacrophages, and based
on our previous studies, we postulate that this factor is likely type
I IFN (35). Reinforcing the biological relevance of phagocytosis
for innate as well as for adaptive immunity, the upregulation of
this mechanism after MVA infection could be important in mod-
ulating the immune response, which in turn can influence the
extent and quality of the host response andprotective efficacy after
vaccination.
Compared to IFN signaling, however, TLR signaling was not
activated in VACV-infected macrophages. TLRs are membrane-
bound receptors that recognize highly conserved molecular pat-
terns among pathogens, such as viral double-stranded RNA
(dsRNA), which is recognized by TLR3. Activation of these recep-
tors leads to a cascade of intracellular events that result in the
activation of the innate immune system (reviewed in reference
43).We observed that all of the poxvirus vectors tested downregu-
lated genes involved in TLR signaling, such as Myd88 and TLRs
(Table 1). This finding, however, was not surprising as VACV
subverts many innate immune response mechanisms by produc-
ing viral proteins that counteract these pathways (44–47), and all
of the vectors used encode the VACV protein A46R that blunts
TLR signaling (48).
Finally, in full agreement with our in vitro apoptosis results, all
of the poxvirus vectors downregulated antiapoptotic genes such as
BCL2 and upregulated inducers of apoptosis, such as Fas ligand or
caspase genes (Table 1). Apoptosis is very important for the effi-
cacy of the innate immune response against pathogen infection
and is generally considered a self-defense mechanism (17) as loss
of host cell activity should impair virus propagation. For instance,
apoptotic cells are engulfed and digested in lysosomes of phago-
cytes. This mode of phagocytic elimination of invading microbes
represents an important innate immune mechanism. In contrast,
viruses appear to resist this host action by inhibiting apoptosis
using antiapoptotic proteins encoded by viral genes (32). More-
over, the phagocytosis of apoptotic bodies seems to be an impor-
tant mechanism to cross-prime macrophages as extracellular an-
tigens gain access to MHC-I molecules for priming of cytolytic T
cells (31). Importantly, MVA and NYVAC modulated signifi-
cantly more apoptosis inhibitors and inducers, again highlighting
their enhanced potential to induce apoptosis via genetic and cel-
lular processes. These results, together with our observations that
infection with MVA and NYVAC led to the modulation of con-
siderably more genes involved in immunomodulation, would
suggest that these attenuated vectors aremore potent activators of
different components of the innate immune system. Specifically,
MVA induced the greatest activation of ISG and type I IFN gene
expression, which was also confirmed at the protein level using
media from MVA-infected macrophages of different donors to
inhibit VSV infection in vitro (Fig. 6) and induce phagocytosis in
naive macrophages (Fig. 7). Likewise, MVA also induced the
greatest amount of apoptosis in infected macrophages, which we
hypothesize could putatively activate the immune system in vivo
via cross-priming with T cells. It is important to note that while
MVA can be genetically modified to reverse its inhibitory effects
on apoptosis signaling and/or tomodulate its ability to activate the
innate immune system, as has been shown by other investigators
(49), our study suggests that there is a correlation between stimu-
lation of innate responses, such as IFN production or apoptosis,
and immune stimulation by the currently available attenuated
poxvirus vectors.
In summary, the data presented here, studying a large panel of
different poxvirus vectors, should serve to advance our understat-
ing of these vectors at the cellular, immune, and molecular levels.
Apart from having conducted an extensive study of the viral life
cycle of nonattenuated and attenuated vaccinia virus vectors in
primary humanmacrophages, we performed in-depth analyses of
the transcriptional changes that occur within infected cells and
discovered many immune-related genes and pathways that are
differentially regulated by each poxvirus. Thus, we hope that the
knowledge gained from these genetic studies will aid vaccine de-
velopment groups in improving or developing new vaccinia virus-
based vaccine vectors which can specifically activate key innate
immune responses, such as type I IFN signaling, apoptosis, and
phagocytosis.
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